Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
01:08pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
01:11pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such inve
Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:26pm, Thursday, 15'th Jan 2026
Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
11:27am, Thursday, 15'th Jan 2026
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NAS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
03:49pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such inve
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 13'th Jan 2026
After losing some value lately, a hammer chart pattern has been formed for Vanda (VNDA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions
Vanda and Exante Data Combine in Strategic Merger
09:31am, Thursday, 08'th Jan 2026
LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macr
Dow Jones Today: Stock Futures Slip After S&P 500, Dow Retreat From Record Highs
09:30am, Thursday, 08'th Jan 2026
Stock futures pointed lower Thursday, a day after the benchmark S&P 500 and blue-chip Dow Jones Industrial Average set fresh all-time highs before retreating.
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
07:00am, Thursday, 08'th Jan 2026
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Cen
Vanda Pharmaceuticals (NASDAQ:VNDA) Reaches New 12-Month High – What’s Next?
02:14am, Friday, 02'nd Jan 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) shares hit a new 52-week high during trading on Wednesday. The company traded as high as $9.00 and last traded at $9.3980, with a volume of
The CNN Money Fear and Greed index showed decline in market sentiment, while stocks closed lower. Nasdaq and S&P 500 recorded gains for 2025.
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
07:40am, Thursday, 01'st Jan 2026
Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and S
